Back to top
more

Owens & Minor (OMI)

(Real Time Quote from BATS)

$12.69 USD

12.69
34,614

+0.89 (7.54%)

Updated Nov 6, 2024 10:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Hold on to Illumina (ILMN) Stock For Now

by Zacks Equity Research

Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.

Patterson Companies (PDCO) Moves Up 12.5%: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) robust segmental performance and strong prospects in the dental space.

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.

Here's Why You Should Hold on to Haemonetics (HAE) For Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.

Has Owens & Minor (OMI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Owens & Minor (OMI) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

Illumina (ILMN) Hurt by Rising Costs, Tough Competition

by Zacks Equity Research

Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.

NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up

by Zacks Equity Research

NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.

Here's Why You Should Hold on to Cardiovascular Systems (CSII)

by Zacks Equity Research

Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists

by Zacks Equity Research

IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.

Here's Why You Should Retain Thermo Fisher (TMO) For Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space

by Zacks Equity Research

Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.

Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth

by Zacks Equity Research

In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes

by Zacks Equity Research

Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.

Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects

by Zacks Equity Research

Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.

Here's Why You Should Retain Amedisys (AMED) Stock For Now

by Zacks Equity Research

Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.

Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer

by Zacks Equity Research

Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.

Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.

Medtronic (MDT) Reports Positive Findings Backing RDN System

by Zacks Equity Research

Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.

Here's Why Owens & Minor (OMI) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Owens & Minor (OMI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.

Is Owens & Minor (OMI) a Great Stock for Value Investors?

by Zacks Equity Research

Is Owens & Minor (OMI) a great pick from the value investor's perspective right now? Read on to know more.